Michelina Dargenio
A5011666578- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Lymphoma Diagnosis and Treatment
- Antifungal resistance and susceptibility
- Childhood Cancer Survivors' Quality of Life
- Fungal Infections and Studies
- Tuberculosis Research and Epidemiology
- Epigenetics and DNA Methylation
- COVID-19 Impact on Reproduction
- Hematological disorders and diagnostics
- Cancer Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Bone and Joint Diseases
- Respiratory viral infections research
- Hematopoietic Stem Cell Transplantation
- Bone health and treatments
- Sepsis Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
Ospedale Vito Fazzi
2009-2024
Inserm
2023
Centre de recherche en Epidémiologie et Santé des Populations
2023
Université Paris-Saclay
2023
Centre Hospitalier de Versailles
2023
University Medical Center Hamburg-Eppendorf
2023
Universität Hamburg
2023
Université de Versailles Saint-Quentin-en-Yvelines
2023
Klinikum rechts der Isar
2023
Azienda Usl Toscana Centro
2023
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and between January 2021 March 2022 were analyzed. A total 1548 cases included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing 753 (49%), the Omicron variant was prevalent (517, 68.7%). Most received ≤2 vaccine doses before (1419, 91%), mostly...
The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. aim present study was to retrospectively analyse the and risk factors for mortality a large series patients who developed infection after an HSCT.This multicenter retrospective promoted by European Hematology Association - Infections Study Working Group, included 326 adult HSCT had between January 2020 March 2022.The median time from diagnosis 268 days (IQR...
BackgroundThe COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, monoclonal antibodies have been effective the general population, their benefits these patients may not be as pronounced.MethodsThe EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers data from malignancy since pandemic's...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes life-threatening COVID-19 in hematologic malignancy (HM) patients, associated with high morbidity and mortality this particularly vulnerable population.1 After more than years since the beginning of pandemic, several prophylactic therapeutic strategies have been developed against SARS-CoV-2, including targeted antivirals, monoclonal antibodies vaccines, leading to improved prognosis HM patients.2 Our preliminary data...
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL studyThe anti-CD38 antibody daratumumab, currently approved for the treatment of patients multiple myeloma, is also being explored leukemia (ALL), whose blasts commonly express high levels CD38. 1 Patients (R/R) disease, as well those positive measurable residual disease (MRD) have consistently shown unfavorable outcomes and, especially T-lineage ALL,...
Bloodstream infections (BSI) caused by Gram-negative bacteria (GNB) in patients with hematological malignancies (HM) have been associated high mortality rates, particularly antibiotic-resistant strains. A multicenter cohort study including all consecutive episodes of GNB BSI HM was conducted to update the epidemiology and antibiotic resistance patterns (compared our previous survey between 2009 2012) investigate risk factors for due multidrug-resistant (MDR) isolates. total 834 were...
Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of patients with haematological malignancies (HM) and Escherichia coli represent one most frequent cause such infections. In this study, we aimed to describe risk factors for resistance third generation cephalosporins prognostic factors, including impact resistance, HM BSIs caused by E. coli. Three hundred forty-two cases were collected during study period (from January 2016 December 2017). The...
Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail.We analyzed elderly (age groups: 65-70, 71-75, 76-80, and >80 years old) included EPICOVIDEHA registry between January 2020 July 2022. Univariable multivariable Cox regression models were conducted to identify factors influencing death hematological malignancy.The study data from 3,603 (aged 65 or older) malignancy, a...
The administration of TKIs after Allo-SCT in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) remains controversial, and the TKI approach (prophylactic, pre-emptive or salvage) is still heterogeneous transplant centers. In this context, very little known about feasibility safety third-generation TKIs. paper, we analyze efficacy ponatinib (PONA) administered to prevent cytologic relapse Ph ALL. This a multicenter observational study including 48 patients (pts) with ALL...
Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression severe SARS-CoV-2 infections decrease hospitalisation mortality rates. Nirmatrelvir/ritonavir was authorised in Europe December 2021, whereas molnupiravir is not yet licensed as of February 2022. may be an alternative because it associated with fewer drug-drug interactions contraindications. A caveat for the mode action induces viral mutations. Mortality rate reduction less pronounced than that patients...
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent (20)19 disease (COVID-19)-related death. The changing epidemiological therapeutic scenarios suggest that there has been improvement in severity survival COVID-19 during the different waves pandemic general population, but this not investigated yet MM patients. Here we analyzed a large cohort 1221 patients with confirmed SARS-CoV-2...
Blinatumomab (Blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, little is known about after recurrence re-treatment with immunotherapy.
Bronchoalveolar lavage (BAL) is recommended for diagnosing lung infiltrates (LI) in patients with hematologic malignancy (HM). Prospective data on the impact of BAL survival are still lacking. We conducted a prospective observational study who performed LI among 3055 HM hospitalized from January to September 2018. The was 145 out 434 developed LI, at median time four days detection. age 60 (1-83). Most had an acute myeloid leukemia/myelodisplastic syndrome (81), followed by lymphoma (41),...
In acute lymphoblastic leukemia, flow cytometry detects more accurately leukemic cells in patients' cerebrospinal fluid compared to conventional cytology. However, the clinical significance of positivity with a negative cytology - occult central nervous system disease is not clear. framework national Campus ALL program, we retrospectively evaluated incidence and its impact on outcome 240 adult patients newly diagnosed leukemia. All samples were investigated by cytometry. The presence ≥10...
The potential drug-drug interactions of midostaurin may impact the choice antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate incidence invasive fungal diseases (IFD) during treatment FLT3-mutated AML patients and to correlate it different AF strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen treated with chemotherapy + as induction/reinduction, consolidation or both were enrolled. During...
Summary We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated ibrutinib and idelalisib clinical practice. Overall, 108 of (29·8%) developed infections, for a total 152 events. Clinically defined (CDI) were 49·3% (75/152) microbiologically (MDI) 50·7% (77/152). Among 250 ibrutinib, 28·8% (72/250) experienced one or more 104 episodes. MDI 49% (51/104). Bacterial 66·7% (34/51), viral 19·6% (10/51) invasive fungal diseases (IFD) 13·7%...
The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) has significantly improved patients' prognosis. Within the Campus ALL network we analyzed outcome Ph-ALL patients treated according to GIMEMA LAL1913 protocol outside clinical trial, compare real-life data with study results. We included 421 consecutive patients, a median age 42 years. complete remission (CR) rate after first course chemotherapy was 94% and measurable residual...
CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML myelodysplasia-related changes (MRC-AML). No extensive data are available on measurable residual disease (MRD) and long-term clinical outcome using in real life. We retrospectively collected from 168 36 centers France Italy who had received 1 2 cycles of induction CPX-351. All were aged >18 years newly diagnosed, untreated t-AML MRC-AML. With a median follow-up 3 years, the overall survival (OS)...